FLASH, Synthetic Hypericin, Clinical Trials, CTCL

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

This study is currently recruiting participants.

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

Study Type:  Interventional

Study Design:

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:  A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Condition:  Cutaneous T-Cell Lymphoma


Drug: SGX301 (synthetic hypericin)
Drug: Placebo

Phase:  Phase 3

External Link:  https://clinicaltrials.gov/ct2/show/study/NCT02448381